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Abstract  
Immunotherapy is a promising new treatment for patients with advanced prostate 
and ovarian cancer but its application is limited by the lack of suitable target 
antigens that are recognized by CD8+ cytotoxic T lymphocytes (CTL). Human 
kallikrein 4 (KLK4) is a member of the kallikrein family of serine proteases that is 
significantly over-expressed in malignant versus healthy prostate and ovarian 
tissue, making it an attractive target for immunotherapy. We identified a naturally 
processed, HLA-A*0201-restricted peptide epitope within the signal sequence 
region of KLK4 that induced potent CTL responses in vitro in most healthy donors 
and prostate cancer patients tested. These CTL lysed HLA-A*0201+ prostate and 
ovarian cancer cell lines expressing KLK4. CTL specific for the HLA-A*0201-
restricted KLK4 peptide were more readily expanded to a higher frequency in 
vitro compared to the known HLA-A*0201-restricted epitopes from prostate 
cancer antigens; prostate specific antigen (PSA), prostate specific membrane 
antigen (PSMA) and prostatic acid phosphatase (PAP). These data demonstrate 
that KLK4 is an immunogenic molecule capable of inducing CTL responses and 
identify it as an attractive target for prostate and ovarian cancer immunotherapy. 
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Introduction  
Metastatic prostate cancer is a disease for which there are currently no effective 
treatments. Harnessing the therapeutic potential of the immune system’s cellular 
response using strategies such as dendritic cell (DC) immunotherapy or adoptive 
T cell therapy is an attractive treatment for patients with metastatic prostate cancer 
because of its potential efficacy, low toxicity and ability to be combined with 
other therapies [1-2]. Testimony to this approach is a recent Phase III clinical trial 
of a vaccine comprised of antigen presenting cells (APC) loaded ex-vivo with a 
prostatic acid phosphatase (PAP)-GM-CSF fusion protein (Sipuleucel-T, 
Dendreon) [3]. This has been one of the few new treatments for metastatic 
prostate cancer to significantly improve patient survival and the first cell-based 
immune therapy to receive US FDA approval.  
Tumor-specific cytotoxic T lymphocyte (CTL) responses are central to the 
induction of anti-tumor immune responses. The identification of tumor-associated 
antigens (TAA) that can serve as CTL targets is essential to the development of 
clinical immune therapies and monitoring their outcomes. The ideal TAA should 
be strongly expressed in tumors and be capable of inducing both CD8+ and CD4+ 
T lymphocyte responses to multiple MHC alleles (i.e. have broad applicability) 
but have limited expression in normal tissues (reducing peripheral TAA tolerance 
and minimizing the risk of induction of autoimmunity). Ideally a TAA should also 
play a significant role in the oncogenic process or cancer cell survival so as to 
minimize selection of TAA loss tumor variants during immunotherapy. A number 
of TAA have been identified for prostate cancer, including PAP, prostate specific 
antigen (PSA, also known as kallikrein 3 (KLK3)), and prostate specific 
membrane antigen (PSMA) [4-9], but none of them meet all the above criteria. 
Furthermore, the use of multiple TAA and several epitopes to maximize responses 
4 
and minimize immune escape by antigen loss tumor variants is now favored by 
clinicians [10]. Thus, the identification of additional, more tumor-specific TAA 
remains an important priority for clinical immunotherapy.  
Human kallikrein 4 (KLK4) is a serine protease belonging to the PSA-related 
kallikrein family [11]. KLK4 is expressed in virtually 100% of prostate cancers 
and is significantly over-expressed in malignant versus normal prostate, with 
weak expression in a limited range of healthy tissues [12-16]. The KLK4 gene 
consists of 5 coding exons and alternative splicing in prostate cancer cells results 
in 2 major transcripts: the full length KLK4-254 transcript and the exon 1 deleted 
KLK4-205 transcript [17]. The KLK4-254 transcript encodes a 254 amino acid 
preproenzyme (KLK4-254) that is predominantly localized to the cytoplasm and 
can be secreted, whereas the KLK4-205 transcript encodes the more abundant N-
terminally truncated 205 amino acid isoform (KLK4-205) that is devoid of a 
signal peptide and pro-region, and is localized to the nucleus. Both protein 
isoforms are over-expressed in prostate cancer. 
Expression of KLK4 is associated with an epithelial to mesenchymal transition 
and proliferation of cell growth in prostate cancer cell lines, suggesting 
involvement in cancer progression [18-19]. This and the over-expression of KLK4 
in most prostate cancers makes it an attractive candidate to target for immune 
intervention. The detection of KLK4-specific antibodies in the serum of prostate 
cancer patients [20] and the identification of naturally processed CD4+ T helper 
cell epitopes [21] provides evidence that KLK4-specific immune responses can be 
induced. Given the importance of CTL responses in the induction of tumor 
immune responses, we investigated whether KLK4-specific CD8+ CTL responses 
could be generated in healthy donors and prostate cancer patients. We identified a 
HLA-A*0201-restricted naturally processed epitope residing within the signal 
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peptide region of the molecule (within the KLK4-254 isoform) that stimulated the 
expansion of specific CD8+ CTL. These data demonstrate that KLK4 is an 
immunogenic molecule and justifies its use as an immunotherapeutic vaccine 
target. 
 
Materials and Methods  
Blood samples. Peripheral blood mononuclear cells (PBMCs) were obtained by 
venepuncture or apheresis from HLA-A*0201 positive healthy donors and 
prostate cancer patients following informed consent obtained under ethical 
approval from the Mater Health Services Human Research Ethics Committee. 
Human AB serum was obtained from the Australian Red Cross Blood Service.  
Antibodies, reagents and cell lines. IL-2 was provided by Roche (Basel, 
Switzerland) and IL-7 and β-2-microglobulin was purchased from Sigma. Prostate 
cancer cell lines LNCaP (HLA-A*0201+) and PC3 (HLA-A*0201-), ovarian 
carcinoma cell lines OVCAR-3 and CaOV3 (both HLA-A*0201+), the 
myelogenous leukemia cell line K562 and the TAP deficient T2 cell line were 
obtained from the ATCC (Manassas, VA) and maintained in the recommended 
media. 
Peptides. Two separate computer algorithms were used to analyze the KLK4 
amino acid sequence for potential HLA-A*0201 binding nonamer peptide 
sequences. The algorithm from the BioInformatics and Molecule Analysis Section 
of the NIH (BIMAS, http://www-bimas.cit.nih.gov) [22] scores potential HLA-
A*0201 binding peptides based on the estimated half-time of dissociation of 
complexes containing peptide at 37oC and pH 6.5, whilst the SYFPEITHI 
algorithm [23] (access via www.syfpeithi.com) scores peptides according to 
amino acids in anchor and auxiliary anchor positions based on published motifs. 
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Peptides with the highest scores obtained from both programs were synthesized 
using standard solid-phase synthesis (Auspep, Parkville, Australia) and stocks 
were reconstituted at 10mg/ml. HLA-A*0201-restricted epitopes from other 
known prostate cancer TAA (PAP-5299-307 ALDVYNGLL; PSA-3154-163 
VISNDVCAQV; PSMA-2711-719 ALFDIESKV (Bachem AG)) were also 
synthesized.  
T2 Binding assay. Peptide binding to HLA-A*0201 was assessed by stabilization 
of HLA-A*0201 molecules on the surface of T2 cells by flow cytometry. T2 cells 
were washed twice in RPMI 1640 and resuspended in X-vivo 15 serum-free 
medium (Cambrex) in the presence of β-2-microglobulin. Serial dilutions of 
KLK4 peptides (50-0.75 μg/mL in dH2O) were added and cells incubated at room 
temperature for 2 hours with occasional gentle re-suspension.  Cells were then 
washed and stained with an anti-HLA-A2 (HB82 supernatant, ATCC) followed 
by sheep anti-mouse FITC (Chemicon) and analyzed by flow cytometry. The 
stabilization ratio was calculated as the mean fluorescence intensity (MFI) of 
HLA-A2 staining of T2 cells pulsed with test peptide (for the peptide 
concentration with the highest MFI) divided by the MFI of control T2 cells 
without peptide at the same peptide concentration.  
CMRF-56+ DC preparation. CMRF-56+ DC preparations were isolated as 
previously described [24]. Briefly, PBMCs were isolated by Ficoll-density 
gradient separation and cultured for 16 hours in RPMI 1640 containing 2 mM 
glutamine, 10 mM HEPES, 1 mM pyruvate, 0.1 mM nonessential amino acids, 
50µM 2-mercaptoethanol and 10% human pooled AB serum (complete medium, 
CM). Cells were harvested and resuspended in cold separation buffer (PBS, 2 mM 
EDTA, 1% human pooled AB serum). Biotinylated CMRF-56 mAb (MMRI) was 
added for 15 minutes at 4°C. Cells were and incubated with anti-biotin 
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microbeads (Miltenyi) for 15 minutes at 4°C. After washing once, cells were 
passed over a MACS LS magnetic column (Miltenyi) according to the 
manufacturer's instructions. For some experiments, CMRF-56+ cells were isolated 
on the CliniMACS machine using the enrichment 1.1 program and TS Tubing set 
(Miltenyi). The positively selected cell fraction was referred to as the CMRF-56+ 
preparation. 
Generation of KLK4 mRNA. cDNA coding for the complete KLK4 sequence 
was ligated into the RNA expression vector pGEM4Z/A64 (kindly provided by Dr 
Eli Gilboa, Duke University Medical Center, Durham, North Carolina, USA), 
using the restriction enzymes Hind III and Xba I. The mRNA expression vector 
was linearized by overnight restriction enzyme digestion with Spe I followed by 
purification using the Qiaquick PCR purification kit (Qiagen). Capped antigen-
encoding mRNA was generated by in vitro transcription using the mMESSAGE 
mMACHINE T7 RNA in vitro translation kit (Ambion, Austin, TX, USA) and 
purified by column centrifugation using the MEGAclear kit (Ambion), according 
to the manufacturers’ instructions.  The quality and quantity of antigen-encoding 
mRNA was established by denaturing agarose gel electrophoresis and 
spectrophotometry.  
Transfection of DC. DC isolated from donor PBMC by CMRF-56+ positive 
selection as described above or monocyte-derived DC (MoDC) differentiated in 
the presence of GM-CSF and IL-4 were transfected with mRNA using a BioRad 
GenePulsar II. Briefly, DC were mixed with mRNA in a 0.2 cm gap cuvette 
(BioRad). Cells were electroporated at 250 V, 150 µF, (BioRad GenePulsar II) 
then incubated on ice for 1 min, prior to resuspension in CM. 
Induction of CTL cultures. The CMRF-56+ preparation was re-suspended in X-
vivo 15 medium and pulsed with peptide (5µg/ml) for 2 hours at room 
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temperature. Either these peptide pulsed cells, or cells transfected as described 
above, were washed once in CM and incubated with autologous PBMC 
responders at a 1:5 ratio in CM, containing IL-7. IL-2 was added on day 3 and 
every 3 days thereafter. Cultures were restimulated with autologous irradiated 
peptide-pulsed PBMC, or transfected CMRF56+ DC on day 12 and then at weekly 
intervals.  
IFN-γ ELISPOT. The induction of peptide-specific T lymphocyte responses in 
the cultures was measured prior to each restimulation using an IFN-γ ELISPOT 
assay kit (Mabtech). In brief, nitrocellulose filtration plates (Millipore) were 
coated overnight at 4ºC with IFN-γ capture antibody. After washing and blocking 
with CM, titrations of harvested CTL cultures were incubated with individual test, 
control or no peptide pulsed T2 cells in the presence of β-2-microglobulin. After 
18 hours culture (37ºC, 5% CO2), the plates were washed with PBS/0.01% Tween 
followed by PBS, and incubated with biotinylated IFN-γ detection antibody for 2 
hours at 37ºC before washing again. Spots were visualized by the addition of 
streptavidin-alkaline phosphatase for 1 hour at 37ºC, followed by Sigma FASTTM 
substrate. Color development was terminated with water, plates were dried and 
spots counted on an automated ELISPOT reader (Autoimmun Diagnostika). All 
dilutions were performed in triplicate against individual peptides and controls. 
The frequency of antigen-specific CTL was calculated from dilutions which fell 
within the linear sensitivity range of the assay and responses were classified as 
antigen-specific only where the number of spots in the test wells were 
significantly greater (p < 0.05 by Student’s unpaired t-test) than those in the 
control wells at the same CTL dilution. The percentage of CD8+ T lymphocytes 
within the cultures was monitored by flow cytometry. Positive responses were 
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then expressed as number of IFN-γ producing cells per 104 or 106 CD8+ T 
lymphocytes from the means of triplicate test minus control wells. 
Clonal expansion of in-vitro generated CTL. When the CTL cultures generated 
greater than 1% specific CTLs detected by ELISPOT, attempts were made to 
isolate and expand clonal antigen-specific CTL using an IFN-γ secretion assay 
(Miltenyi). Briefly, cultures were incubated with specific peptide- or control-
pulsed T2 cells overnight, then stained with IFN-γ catch reagent followed by 
incubation in CM for 45min at 37oC to trap IFN-γ on the surface of secreting 
cells. Cells were stained with a PE-conjugated IFN-γ detection antibody along 
with anti-CD3-FITC, CD4-APC, CD8-PerCPC5.5 and CD56-PECy7. Single IFN-
γ+ CD3+CD8+CD56- events were sorted by flow cytometry into round-bottom 
plates and expanded with irradiated allogeneic PBMC in the presence of 
phytohemagglutinin (PHA) and IL-2. Specificity of the expanded clones was 
tested by 51Cr release assay using peptide-pulsed T2 cells as targets. Clones were 
maintained in CM containing 100U/ml IL-2 with intermittent restimulation with 
irradiated allogeneic PBMC and PHA as required.  
Cytotoxicity Assay. A standard 4 hr chromium (51Cr) release assay was used to 
examine the CTL cytotoxic capacity against peptide-pulsed T2 cells and tumor 
cell lines. Washed targets were labeled with 100 μCi 51Cr and incubated with 
titrated doses of CTL for 4 hours in the presence of excess K562 cells to saturate 
any non-specific NK-mediated lysis. Culture supernatants were harvested and 
counted on a Microbeta Trilux β-scintillation counter (Wallac). Percent specific 
lysis was calculated as 100 x (test count–spontaneous release control count) / 
(total release control count–spontaneous release control count). 
Pentamer Analysis. Induction of peptide specific MHC-class I restricted CTL 
was determined using pentamer technology prior to each stimulation. Briefly, 
10 
CTL cultures were stained with the relevant Peptide/MHC APC-conjugated 
pentamers (Proimmune) in PBS/0.2% human serum albumin for 10 mins at room 
temperature followed by staining with anti-human CD4-APC-Cy7, CD8-PE, 
CD3-FITC, CD14-PerPC, CD19-PerCP and 7-aminoactinomycin D (all BD). 
Cells were washed and analyzed on a BD LSRII flow cytometer. Pentamer 
positive cells were determined as those that were CD14/19/7AAD negative, 
CD8/pentamer positive. A no pentamer stained control was used to set the gating 
strategy.  
Reverse transcription–PCR (RT–PCR). Total RNA was isolated from cancer 
cells using TRIzol reagent (Invitrogen, Mount Waverley, VIC, Australia), treated 
with RNasefree DNase I (Invitrogen) and reverse-transcribed with random 
hexamers pd(N)6 (Roche Diagnostics, Brisbane, Queensland, Australia) and 
Superscript II (Invitrogen). PCR with KLK4-specific primers K4Ex1ATGS (5’-
ATGGCCACAGCAGGAAATCCC-3’) and K4Ex4AS (5’-
CACGCACTGCAGCACGGTAG-3’), (detects full length KLK4-254 transcript 
that includes the signal peptide codon) or K4Ex2S (5’-
GCGGCACTGGTCATGGAAAACG-3’) and K4Ex5AS (5’-
CAAGGCCCTGCAAGTACCCG-3’ was performed with 1 μl cDNA, 0.5 units 
platinum Taq DNA polymerase (Invitrogen) and 35 cycles with annealing 
temperatures of 62ºC. PCR for β2-microglobulin, which gave a 249 bp amplicon 
used as an internal control for RNA integrity, was performed using forward (5’-
TGAATTGCTATGTGTCTGGGT-3’) and reverse (5’-
CCTCCATGATGCTGCTTACAT-3’) primers for 32 cycles with similar PCR 
conditions. The PCR products were electrophoresed on a 1% (w/v) agarose gel 
and visualized by ethidium bromide staining. 
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Results 
Induction of KLK4 peptide-specific CD8+ T lymphocyte responses in healthy 
donors and prostate cancer patients.   
We used two computer algorithms to identify several nonamer peptide sequences 
from KLK4 that were predicted to bind efficiently to HLA-A*0201. Five peptides 
with the highest binding scores from both algorithms (designated KLK4A-E) were 
synthesized. The KLK4A peptide sequence is located in the signal sequence 
region of exon 1 that is only present in the KLK4-254 isoform, whilst the peptide 
sequences B-E are located downstream in regions common to both KLK4-254 and 
KLK4-205 isoforms. The 5 peptides all bound HLA-A*0201 with similar or 
higher affinity compared to the control strong HLA-A*0201 binding epitope from 
influenza A matrix protein (FluMP), and known HLA-A*0201 eptiopes from 
prostate cancer TAA PAP, PSA and PSMA, as indicated by stabilization ratios of 
greater than 1.4 in a T2 binding assay (Table 1). The KLK4A exon 1 signal 
sequence peptide had the highest affinity for HLA-A*0201 as predicted by both 
algorithms. 
To induce KLK4-specific CD8+ CTL responses we pulsed CMRF-56+ blood DC 
from HLA-A*0201+ donors with the pooled KLK4A-E peptides and used the 
pulsed DC to stimulate autologous PBMC. Cultures were restimulated with 
peptide-pulsed PBMC at weekly intervals and the induction of individual peptide 
specific responses was monitored by IFN-γ ELISPOT (Figure 1a). A response to a 
given peptide was considered positive only if the number of IFN-γ spots were 
significantly higher than the number of spots following re-stimulation with and 
irrelevant control peptide (Online resource 1).  We observed strong IFN-γ 
production specific for the KLK4A peptide in 2 healthy donors and significant but 
lower responses in a further 2 healthy donors (Figure 1a). These responses were 
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observed in both females (donors 1,  and 3, ○, Figure 1a) and males (donors 2, □ 
and 4, ◊ Figure 1a). The maximum percentage of specific IFN-γ-producing cells 
was observed between 2-5 stimulations. Weaker responses specific for the 
KLK4B, C, D and E peptides were induced in some, but not all, healthy donors 
(Figure 1a, open symbols).   
Cancer patients’ immune systems are often compromised as a result of the 
malignancy itself or treatment regimens [25]. We therefore examined whether 
prostate cancer patients at various stages of their disease could generate KLK4-
specific immune responses. Strong KLK4A-specific responses, similar in 
magnitude to the responses induced in healthy donors, were induced in 4 / 6 
prostate cancer patients and unequivocal but weak responses induced in a further 
2 patients (Figure 1a, closed symbols). We also observed responses to the 
KLK4B, C, D and E peptides in several donors, however these were considerably 
lower than the responses specific for KLK4A. These data demonstrate that HLA-
A*0201-restricted responses specific for KLK4 can be generated in both male and 
female healthy donors as well as prostate cancer patients, with the strongest 
response being to the KLK4A epitope.  
To confirm the immunogenicity of KLK4A, KLK4A/HLA-A*0201 pentamers 
were synthesized and used to monitor the induction of KLK4A-specific responses 
in vitro (Figure 1b). Consistent with the IFN-γ ELISPOT data, KLK4A/HLA-
A*0201-specific CTL were expanded in 2 healthy donors and 8/10 prostate cancer 
patients (2 representative donors shown in Figure 1b). Five of these donors were 
included in the cohort tested by ELISPOT and demonstrated similar results 
between the two assays. A summary of the induction of KLK4A pentamer-
specific CTL in healthy donors and prostate cancer patients is shown in Table 2. 
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Therefore, KLK4A appears to be an immunogenic peptide that induces CTL 
responses in most healthy donors and prostate cancer patients.   
 
Isolation and expansion of CTL clones specific for KLK4A and KLK4C.  
CTL specific for the KLK4A and KLK4C peptides were isolated from the 
polyclonal cultures derived from a male healthy donor using an IFN-γ secretion 
assay and cloned by limiting dilution. Two CTL clones specific for KLK4A and 
four clones specific for KLK4C were expanded and analyzed to establish their 
specificity and functionality. Specificity of the KLK4A clones was confirmed by 
pentamer staining (Online resource 2). All CTL clones secreted IFN-γ in response 
to T2 cells pulsed with their respective peptides, but not in response to control 
peptide pulsed T2 cells in ELISPOT assays (Figure 2a,b). Each clone also lysed 
T2 cells pulsed with the respective KLK4A or C peptides but not control T2 cells 
in a 51Cr release assay (Figure 2c,d). Clones specific for the KLK4A peptide did 
not cross-react with other HLA-A*0201-restricted peptides KLK4B-E in IFN-γ 
ELISPOT assays (Figure 2e). Likewise, anti-KLK4C CTL clones recognized the 
KLK4C peptide exclusively and did not cross-react with peptides KLK4A, B, D 
or E (Figure 2e). Next, we investigated the affinity of the CTL clones by 
examining their ability to recognize T2 cells pulsed with titrating doses of specific 
peptide (Figure 2f). Clones specific for KLK4C showed reactivity down to 5-
50pg/ml of specific peptide, whereas KLK4A clones had an even higher affinity, 
reacting to as little as 0.5pg/ml of specific peptide. These data demonstrated that 
functional CTL clones with specificity for the HLA-A*0201-restricted peptides 
KLK4A and C could be expanded after in vitro stimulation. 
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CTL specific for KLK4A but not KLK4C peptides recognize and lyse KLK4-
expressing tumor cells. 
To determine whether the KLK4A and C peptides are endogenously processed 
and presented by tumor cells, we tested the ability of the KLK4A and C specific 
CTL clones to lyse KLK4-expressing tumor cell lines. First, we confirmed mRNA 
expression of both KLK4-254 and KLK4-205 transcripts in the target HLA-
A*0201+ prostate cancer cell line LNCaP and ovarian carcinoma cell lines CaOV3 
and OVCAR-3 (Figure 3a). HLA-A2+ expression was confirmed by flow 
cytometry (Online resource 3a). CTL specific for the KLK4A peptide lysed the 
LNCaP and CaOV3 cell lines but not the control PC3   (HLA*0201-) or OVCAR-
3 cell line that has previously been reported to be resistant to CTL lysis [26] 
(Figure 3b). The percentage of specific lysis of LNCaP cells was low but 
consistent with their low levels of HLA-A2 expression and to lysis by CTL 
against other HLA-A2-restricted prostate cancer antigens [27-28] and lysis by a 
CTL clone specific for an immunodominant HLA-A2-restricted epitope from 
influenza matrix protein, following pulsing of LNCaP with the respective peptide 
(Online resource 3). CaOV3 cells were also lysed by KLK4A-specific CTL to a 
similar extent as lysis by other HLA-A2-restricted ovarian cancer CTL [26]. 
These data demonstrate that the KLK4A epitope is naturally processed and 
presented by HLA-A*0201+KLK4-254+ tumor cell lines. KLK4A-specific CTL 
also lysed MoDC targets that had been transfected with mRNA encoding the 
KLK4-254 transcript (Fig 3c). KLK4 mRNA expression following transfection of 
MoDC was confirmed up to 48hrs post-transfection, however as KLK4 is secreted 
we were unable to confirm the % of MoDC expressing KLK4 (Online resource 4). 
Therefore low levels of KLK4 expression by MoDC might account for the low 
levels of lysis observed. Furthermore, KLK4A pentamer-specific CD8+ T cells 
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could be expanded in a prostate cancer patient using KLK4-254 mRNA-
transfected autologous MoDC as stimulators (Fig 3c). This demonstrates that the 
KLK4A epitope is also endogenously processed by MoDC. In contrast, the 
KLK4C CTL clones failed to lyse any of the cell lines tested (Figure 3b) despite 
their capacity to lyse KLK4C peptide pulsed T2 cells very efficiently at low 
effector:target ratios in the same assay (Figure 2d). These data suggest that the 
KLK4A epitope, but not the KLK4C epitope, is endogenously processed and 
presented and may be a relevant vaccine candidate. 
 
KLK4A-specific CD8+ T cells are more readily expanded in vitro compared to 
PSMA711-719, PSA154-163 and PAP299-307 peptides.  
HLA-A*0201-restricted epitopes that induce CTL responses in prostate cancer 
patients and healthy donors have been identified in prostate cancer TAA PSMA, 
PSA and PAP [4-9]. We compared the ability to expand CD8+ T cells specific for 
these epitopes with the induction of KLK4A-specific CD8+ T cells in prostate 
cancer patients. Similar percentages of KLK4A and PSMA711-719-specific T cells 
could be detected directly ex vivo in the PBMC of most donors (Figure 4a). In 
contrast the frequency of PSA154-163 and PAP299-307-specific T cells was much 
lower or below the limit of detection in the same donors (Figure 4a). After several 
rounds of peptide specific in vitro stimulation, significantly higher frequencies of 
KLK4A-specific CD8+ T cells were induced compared to PSA154-163 and PAP299-
307 –specific T cells (Figure 4b). The percentage of KLK4A-specifc CD8+ T cells 
was also higher than that of PSMA711-719–specific T cells in 5/6 donors (Figure 
4b). In a further 9 healthy donors and 7 prostate cancer patients we were unable to 
expand PSA154-163 and PAP299-307-specific T cells after up to 6 rounds of 
stimulation (data not shown). These data demonstrate that CTL-specific for the 
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KLK4A epitope are more readily expanded than other HLA-A2-restricted prostate 
cancer epitopes in current clinical use. 
 
Signal peptide sequences are rich in putative HLA-A*0201-restricted 
epitopes. 
One of distinguishing features the KLK4A peptide, compared to the KLK4B-E 
and PSMA711-719, PSA154-163 and PAP299-307 epitopes, is its locality within the 
signal sequence region of the molecule. Hydrophobic signal peptides are known to 
associate with HLA-A*0201 [29-30] and a few have been shown capable of 
inducing tumor-specific CTL responses [31-34]. We reasoned that the signal 
peptide regions of KLK4 and related kallikrien family members would be a source 
of putative immunogenic TAA. To investigate this we identified the top 20 
predicted HLA-A*0201-binding peptides from the full-length sequences of 
KLK2,3(PSA),4,5,6,7,8,11,14, and 15 using computer algorithms BIMAS and 
SYFPEITHI. The TAA tyrosinase, MUC1 and calcitonin that have known 
immunogenic HLA-A*0201-restricted epitopes within their signal peptide regions 
were also included. Despite the signal peptides comprising only a small 
proportion (mean 9%) of the full length molecules, they contained a high 
percentage (mean 27%) of the top 20 putative HLA-A*0201-binding epitopes 
(Figure 5a). HLA-A*0101 and HLA-A*0301 binding peptides were also 
identified within the signal sequence molecules, however there were significantly 
lower percentages of these compared to HLA-A*0201-binding peptides (Figure 
5b). These data suggest that signal sequences peptides of KLK4 and other 
kallikrein family molecules could be a rich source of HLA-A*0201-restricted 
epitopes to harness for immunotherapy. 
17 
Discussion 
The identification of new immunogenic prostate cancer TAA is essential to 
develop effective immunotherapy for this disease. Using the “reverse 
immunology” approach, we identified an immunogenic HLA-A*0201-restricted 
CTL epitope within the signal peptide region of KLK4 which we termed KLK4A.  
CTL specific for KLK4A could be expanded from most healthy donors and 
prostate cancer patients in vitro. Most importantly, the KLK4A epitope was 
endogenously processed and presented by tumor cells and MoDC, allowing the 
KLK4A-specific CTL to lyse target cancer cell lines expressing KLK4 and HLA-
A*0201. Furthermore, KLK4A-specific CTL were more readily expanded to 
higher frequencies than HLA-A*0201-restricted epitopes from known prostate 
cancer TAA, PSA and PAP, and were at least as effective as PSMA. KLK4 thus 
represents a new immunogenic prostate cancer target that could be utilized as an 
alternative or in addition to those prostate cancer TAA used in current clinical 
trials. 
In addition to its ability to induce potent CTL responses, KLK4 is a particularly 
attractive therapeutic vaccine candidate for the following reasons. Its 
overexpression in the majority of prostate cancers but much reduced levels in 
healthy tissue limits the potential for deleterious autoimmune side effects. The 
documented role of KLK4 in contributing to prostate cancer development and 
progression minimizes the risk of immunoselecting KLK4-negative variants. 
Furthermore, CD4+ T helper responses are now considered crucial in maintaining 
effective CTL responses and a number of MHC Class II-restricted epitopes within 
KLK4 have been identified [21]. KLK4 is highly expressed in ovarian cancers [35-
36], and our data showed that KLK4A-specific CTL could lyse an ovarian cancer 
cell line. KLK4 is elevated in breast cancer stromal cells [37], which are also 
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relevant vaccine targets [38]. Thus the utility of KLK4 as an effective TAA could 
be applicable to immunotherapy not only for prostate cancer but for the wider 
application to hormone-dependent cancers. 
 
Interestingly, the immunogenic KLK4A epitope was located within the signal 
sequence region that is expressed only by the less abundant but more prostate 
cancer specific KLK4-254 isoform. The location of the epitope within the signal 
sequence may explain why KLK4A-specific CTL responses were readily induced 
in both healthy donors and prostate cancer patients. Signal peptide molecules are 
known to associate with HLA-A*0201 molecules [29-30] and their capacity to 
induce CTL has been documented in a few cases [31-34,39-40]. Epitopes derived 
from signal peptides can be directly processed and presented on MHC Class I 
when expressed endogenously by tumor cells or DC (direct presentation) [40]. 
However, they are not efficiently cross-presented by DC, which is proposed as the 
mechanism by which peripheral tolerance to self antigens is generated [40]. Naïve 
T cells specific for epitopes that are not cross-presented by DC would be unlikely 
to be deleted during thymic selection or induced to be tolerogenic. This would 
imply that a repertoire of naïve CTL precursors specific for signal peptides may 
be available for expansion in both healthy donors and cancer patients. Our data 
provides one example since we were able to more readily detect and expand CTL 
specific for the KLK4A epitope compared to other HLA-A*0201-restricted 
peptides such as PSA154-163, PAP299-307 and KLK4B,D,E that are located in their 
respective core proteins. In support of this theory, HLA-A*0201-restricted 
immunogenic epitopes have been identified within the signal peptides of other 
human TAA, including the melanoma antigen tyrosinase [32-33] and the 
medullary thyroid and lung carcinoma associated CALCA gene [31]. Notably, a 
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HLA-A*0201-restricted epitope is located within the signal sequence of MUC1 
and is immunodominant in breast cancer patients compared to a HLA-A*0201-
restricted epitope located in the MUC1 core protein tandem repeat [34,41].  
Our data suggests that in addition to KLK4, signal sequences of other kallikrein 
family members may also be a rich source of HLA-A*0201-restricted peptides, 
which may potentially be immunogenic for the reasons outlined above. An array 
of kallikrein family members are overexpressed in hormone-dependent cancers 
and many are associated with disease progression and poor prognosis [11,42]. The 
majority (KLK4-11,14,15) are overexpressed in ovarian cancer and many of these 
(KLK4-7, 10,15) are associated with later stage disease and decreased survival. 
KLK14 and 15 are associated with disease progression in prostate cancer, whilst 
KLK5 and 14 are associated with breast cancer. KLK5,6,7,10,11,14 have also been 
associated with poor prognosis in colorectal cancers [42]. For these malignancies 
there are few suitable TAA currently available. Based on our data, exploration of 
the signal peptide regions of the kallikrein family may reveal a new source of 
TAA that could extend the potential of immunotherapy as a treatment for these 
diseases.  
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Figure Legends 
Figure 1 Induction of KLK4-specific CTL responses in healthy donors and 
prostate cancer patients 
DC were loaded with pooled KLK4 peptides A-E and used to stimulate 
autologous PBMC. Induction of peptide specific responses was assessed by 
ELISPOT (a) or pentamer (b).  
a. Maximum responses specific for each KLK4 peptide induced after 2-5 
stimulations in healthy donors ( -40 year old female; □-46 year old male; ○-25 
year old female; ◊- 45 year old male) and prostate cancer patients ( *- 70 year old 
male with hormone refractory disease and bony metastases; ● -76 year old male 
who had undergone radical prostatectomy followed by biochemical recurrence 
and hormone sensitive disease; ♦- 68 year old male with hormone sensitive 
disease; ■- 53 year old male with hormone naïve disease;   - 74 year old male 
with stage T2a disease; ▼- 73 year old male with hormone refractory disease and 
nodal metastases). Data represent the number of specific IFN-γ producing CD8+ T 
cells (KLK4 peptide minus T2 control).  b. Induction of KLK4A-specific CTL 
was analyzed using a KLK4A/HLA-A*0201-specific pentamer from whole 
PBMC (precursor frequency, PF) or after 3 or 4 stimulations. Two individual 
donors are shown. Values in the upper right quadrants are the number of pentamer 
positive events as a percentage of the total CD8+ T cells.  
 
Figure 2 Isolation of CD8+ CTL clones specific for KLK4 peptides A and C  
CTL clones specific for KLK4A (a,c) or KLK4C (b,d) were isolated from 
polyclonal CTL by an IFN-γ secretion assay followed by flow cytometry sorting 
and cloning by limit dilution. The specificity of each clone was assessed by 
examining the number of IFN-γ producing cells by ELISPOT following 
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stimulation with T2 cells pulsed with specific peptide or control (a,b) and by their 
capacity to lyse T2 cells pulsed with specific but not control pulsed peptide by 
51Cr release assay (c,d) E:T ratios were A5=29:1, A41=46:1, all C clones=25:1. e. 
Clones specific for KLK4A (A5) or KLK4C (C39) were screened for reactivity 
against KLK4 peptides A-E by ELISPOT and shown not to cross-react with other 
KLK4 peptides. f. KLK4A (A5) and KLK4C (C17) clones recognize target 
MHC/peptide complexes with high affinity down to peptide concentrations of 
5pg/ml. 
 
Figure 3 KLK4A but not KLK4C is endogenously processed and presented 
by tumor cells and DC 
a. Expression of KLK4-254 (Exon 1-4) and KLK4-205 (Exon 2-5) transcripts in 
the prostate cancer cell lines LNCaP (HLA-A*0201+), PC-3 (HLA-A*0201-) and 
ovarian cancer cell lines CaOV3 and OVCAR-3 (both HLA-A*0201+) by PCR. b. 
LNCaP and CaOV3 cell lines are lysed by a CTL clone specific for KLK4A but 
not by a CTL clone specific for KLK4C in a 51Cr release assay. c. KLK4A is 
endogenously processed by MoDC. Left: A KLK4A CTL clone lysed KLK4 
mRNA-transfected MoDC but not control MoDC in a 51Cr release assay. Right: 
KLK4 mRNA-transfected MoDC were used to stimulate autologous CD8+ T cells 
and the induction of KLK4A-specific CTL was monitored using a KLK4A-
specific pentamer (lower panel) or no pentamer as a control (upper panel).   
 
Figure 4 KLK4A induces similar responses compared with PSMA711-719 and 
superior responses compared to PSA154-163 and PAP299-307 peptides 
a. Precursor frequency of pentamer+CD8+ T cells in prostate cancer patients’ 
PBMC measured using specific MHC/peptide pentamers. b. Maximum induction 
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of peptide specific T cells after up to 5 stimulations in prostate cancer patients 
(filled symbols) and a male healthy donor (open symbol). Each symbol represents 
the same donor for each peptide. * p<0.05 by ANOVA.  
 
Figure 5 Signal sequence peptides from human kallikrein molecules are rich 
in putative HLA-A*0201-restricted epitopes.  
a. Sequences from KLK2,3,4,5,6,7,8,11,14 and 15 were analysed for their top 20 
putative HLA-A*0201-binding peptides using computer algorithms. Included for 
comparison were PAP, tyrosinase (TYR), preprocalcitonin (CALC), and MUC1. 
The filled portions of the histograms represent the percentage of the signal 
sequence expressed as a proportion of the full length molecule. The open portions 
represent the percentage of the top 20 putative HLA-A*0201-binding peptides 
that are located within the signal sequence. b. Signal sequences contain 
significantly lower percentages of HLA-A*0101 and HLA-A*0301 putative 
binding epitopes compared to HLA-A*0201. Data represent the mean + SEM of 
the percentage of putative top 20 binding epitopes for each allele located within 
the signal sequence for the molecules analyzed in a.  
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 Table 1. Peptide sequences, predicted binding and stabilization of HLA-A2 on T2 cells.  
Name Peptide 
Position 
Peptide 
Sequence 
Peptide 
Purity 
SYFPEITHI 
score 
BIMAS 
score 
HLA-A2 
stabilization 
ratio 
KLK4 A KLK411-19  FLGYLILGV  87% 27 736 2.2 
KLK4 B KLK495-103  QMVEASLSV  89% 23 306 1.6 
KLK4 C KLK4164-172  VLQCVNVSV  70% 25 118 1.5 
KLK4 D KLK4160-168  RMPTVLQCV  91% 22 116 1.5 
KLK4 E KLK459-67  VLVHPQWVL  91% 22 112 1.8 
PSA-3 PSA154-163  VISNDVCAQV 95% 21 16.26 1.7 
PAP-5 PAP299-307 ALDVYNGLL 99% 23 1.11 2.2 
PSMA-2 PSMA711-719  ALFDIESKV 95% 26 1055 1.5 
FluMP FMP58-66 GILGFVFTL 95% 30 551 1.4 
 
Table 1 - Peptide sequences, predicted binding and stabilization of HLA-A2 
on T2 cells. The sequences and amino acid positions of 5 KLK4 peptides are 
shown. Predicted HLA-A2 binding based on 2 online algorithms is shown 
(arbitrary scores), as well as HLA-A2 stabilization ratios in a standard T2 binding 
assay. The KLK4 peptide HLA-A2 binding scores and stabilization ratios were 
compared with those of previously used proven HLA-A2 specific peptides.
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 Table 2.  KLK4A specific CTL responses in healthy 
donors and prostate cancer patients. 
Donor type 
 
CD8
+
 Pentamer
+
 cells 
 PF Max Response 
Healthy 0.07 0.10 
Healthy 0.13 0.93 
Healthy 0.53 3.44 
Healthy 0.12 0.24 
Healthy 0.58 11.00 
PC 0.10 0.15 
PC 0.10 80.00 
PC 0.13 1.30 
PC 0.72 21.30 
PC 0.23 4.46 
PC 0.10 5.13 
PC 0.24 1.29 
PC 0.10 7.25 
PC 0.40 3.37 
 
Table 2 - KLK4A specific CTL responses in healthy donors and prostate 
cancer patients. Induction of KLK4A-specific CTL was analyzed using a 
KLK4A/HLA-A*0201-specific pentamer from whole PBMC (precursor 
frequency, PF) or after a number of restimulations which gave the maximum 
response (varied between donors, most commonly 3-4 restimulations). Data 
shown represents the percentage of CD8+ T cells specific for KLK4A. A pentamer 
specific response was demonstrated in 2/5 healthy and 8/9 PC donors. 
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